Dermal and melanocortin research
MT-2
Lyophilized dermal or melanocortin research peptide
Free standard shipping to eligible destinations · estimated 7–11 business days after dispatch
Not a drug, food, dietary supplement, cosmetic, or medical product. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, mitigate, or prevent disease. These materials have not been evaluated by the U.S. Food and Drug Administration.
Receive optional catalog and documentation updates. You can withdraw at any time.
Get catalog updatesProduct record
Specifications and documentation
- Product identity
- MT-2
- CAS number
- Available in product documentation
- Molecular weight
- Available in product documentation
- Purity / assay
- 98.7%-99.2%
- Form
- Lyophilisiertes Pulver
- Configuration
- 10 mg
- Lagerung
- Verschlossen, kalt, trocken und vor Hitzeschwankungen geschützt aufbewahren. Bestätigen Sie die produktspezifische Lagerung bei der Ankunft.
- Analysezertifikat
- Available on request from support
Molecular class
Cyclic seven-residue melanocortin analog
Sequence / composition
An acetylated cyclic alpha-MSH analog containing norleucine and D-phenylalanine residues.
Research design note
Cyclization and non-native residues differentiate this construct from native alpha-MSH and broaden its receptor research profile.
External reading
Literature for context
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Keep comparing
Compare other catalog records.
Explore related research materials. These are not a combined-use recommendation.
-
Dermal
Public product preview
MT-1
Melanotan I / afamelanotide is an alpha-MSH analog research peptide tied to melanocortin receptor and pigment biology literature.
-
Incretin research
Public product preview
AZ-GLP2(T)
Tirzepatide is a dual GIP / GLP-1 receptor agonist reference point in metabolic research and comparative incretin pharmacology.
-
Incretin research
Public product preview
GLP2(M)
Mazdutide sits in the GLP-1 / glucagon dual-agonist research lane, where interest centers on incretin signaling, energy expenditure, and metabolic markers.